應(yīng)用SF-36量表評(píng)估中軸型SpA患者非甾體抗炎藥治療后生活質(zhì)量變化
[Abstract]:Aim: to evaluate the changes of quality of life (QOL) in patients with axial spinal arthritis (SF- 36) treated with non-steroidal anti-inflammatory drug (NSAIDs) (NSAID). Methods: from October 2014 to September 2015, 120 patients with axial Sp A were selected from the first affiliated Hospital of Zhengzhou University. All agreed to use the designated drug and scale evaluation, and signed an informed consent form. A randomized, double-blind, parallel-controlled method was used to divide the two groups into two groups: Ereiclob group and celecoxib group. The two groups were treated twice a day for 3 months at 200 mg, per day. The two groups were divided into two groups: the control group and the celecoxib group. The quality of life (QOL) of axial Sp A patients before and after NSAIDs treatment was evaluated by Chinese version of SF- 36 scale. To analyze the correlation between quality of life (QOL) and erythrocyte sedimentation rate (ESR), C) (CRP), Bath AS disease activity index (BASDAI), Bath), ankylosing spondylitis function index (BASFI), Canadian Spinal Arthritis Research Association score (SPARCC). Results: one hundred and sixteen patients with axial Sp A completed final evaluation and 4 missed follow-up. SF 36 scale was used to evaluate the quality of life (QOL) of axial Sp A patients before and after NSAIDs treatment for 3 months. There was no significant difference between the two drugs (P0.05). After 3 months of NSAIDs treatment, there were significant differences in physiological function, physical pain, general health, social function and emotional function between the two groups (P0.05). There was no significant difference in vitality and mental health (P0.05). There was a positive correlation between BASDAI and PF,RP,BP,GH,VT,SF,RE (P0.05). There was no significant correlation between); BASDAI and MH (P0.05). There was a positive correlation between BASFI and PF,RP,BP,GH,SF,RE,MH (P0.05); BASFI and VT (P0.05). ESR was only positively correlated with SF,RE (P0.05); CRP was only positively correlated with SF,MH (P0.05). SPARCC was only positively correlated with PF (P0.05). BASDAI, BASFI was an important factor affecting PF (P0.05); BASDAI was an important factor affecting BP,GH,VT,RE (P0.05); BASFI is an important factor influencing RP,SF,MH (P0.05). Conclusion: non-steroidal anti-inflammatory drugs can improve the quality of life of patients with axial Sp A, and the efficacy of erracoxib and celecoxib is the same as that of celecoxib, and the SF- 36 scale can be used to evaluate the quality of life of patients with axial Sp A.
【作者單位】: 鄭州大學(xué)第一附屬醫(yī)院河南省高等學(xué)校臨床醫(yī)學(xué)重點(diǎn)學(xué)科開(kāi)放實(shí)驗(yàn)室風(fēng)濕免疫科;中國(guó)人民解放軍總醫(yī)院第一附屬(304)醫(yī)院風(fēng)濕免疫科;
【基金】:河南省科技廳基礎(chǔ)研究項(xiàng)目 河南省高等學(xué)校重點(diǎn)科研項(xiàng)目計(jì)劃(No.16A320011)
【分類號(hào)】:R593.2
【參考文獻(xiàn)】
相關(guān)期刊論文 前3條
1 高冠民;鄭曉龍;李艷敏;江東彬;張蕾蕾;徐鵬慧;劉升云;鄭朝暉;蔣莉;闞全程;;艾瑞昔布和塞來(lái)昔布對(duì)中軸脊柱關(guān)節(jié)炎療效和安全性的隨機(jī)雙盲試驗(yàn)[J];中國(guó)新藥與臨床雜志;2016年09期
2 吳建賢;張松東;;SF-36量表在腰椎間盤突出癥非手術(shù)治療中的應(yīng)用現(xiàn)狀[J];中華臨床醫(yī)師雜志(電子版);2016年01期
3 徐東;張奉春;古潔若;徐建華;陶怡;張鳳肖;何培根;鮑春德;肖衛(wèi)國(guó);;艾瑞昔布治療膝骨關(guān)節(jié)炎的Ⅲ期多中心隨機(jī)雙盲臨床試驗(yàn)[J];中華臨床免疫和變態(tài)反應(yīng)雜志;2014年03期
【共引文獻(xiàn)】
相關(guān)期刊論文 前9條
1 李艷敏;鄭曉龍;江東彬;張蕾蕾;徐鵬慧;高冠民;;應(yīng)用SF-36量表評(píng)估中軸型SpA患者非甾體抗炎藥治療后生活質(zhì)量變化[J];中國(guó)免疫學(xué)雜志;2017年07期
2 詹平;戴閩;楊康驊;李明軍;張斌;尚江蔭子;于小龍;;艾瑞昔布與吲哚美辛預(yù)防肘關(guān)節(jié)周圍骨折術(shù)后異位骨化的比較研究[J];江西中醫(yī)藥;2017年01期
3 黃裕;姚文鳳;李哲琳;周玉球;寧阿妹;陳火玲;覃婉容;;中藥蠟療護(hù)理對(duì)氣滯血瘀型腰椎間盤突出癥患者生活質(zhì)量的影響[J];中華全科醫(yī)學(xué);2017年01期
4 高冠民;李艷敏;鄭曉龍;江東彬;張蕾蕾;鹿莉;唐俊根;郭艷柯;徐鵬慧;劉升云;鄭朝暉;闞全程;;艾瑞昔布和塞來(lái)昔布對(duì)中軸脊柱關(guān)節(jié)炎療效及血清Dickopff相關(guān)蛋白1水平的影響[J];中華風(fēng)濕病學(xué)雜志;2016年12期
5 高冠民;李艷敏;鄭曉龍;江東彬;張蕾蕾;徐鵬慧;劉升云;鄭朝暉;闞全程;;兩種劑量艾瑞昔布和塞來(lái)昔布對(duì)中軸脊柱關(guān)節(jié)炎療效的隨機(jī)對(duì)照研究[J];中國(guó)醫(yī)院藥學(xué)雜志;2017年02期
6 韋盛旺;;艾瑞昔布超前鎮(zhèn)痛對(duì)患者前交叉韌帶重建術(shù)后的鎮(zhèn)痛療效[J];北方藥學(xué);2016年12期
7 張玉明;周敬杰;張明;翟宏偉;張小林;郭和東;;水中核心穩(wěn)定訓(xùn)練對(duì)腰椎間盤突出癥患者的療效觀察[J];中華臨床醫(yī)師雜志(電子版);2016年23期
8 鄭西希;鄭文潔;張奉春;;艾瑞昔布治療膝骨關(guān)節(jié)炎的Ⅳ期多中心開(kāi)放臨床試驗(yàn)[J];中華風(fēng)濕病學(xué)雜志;2016年11期
9 陳建洪;吳桂紅;鄧莎;;艾瑞昔布片治療退行性膝關(guān)節(jié)炎的臨床療效觀察[J];臨床合理用藥雜志;2016年16期
【相似文獻(xiàn)】
相關(guān)期刊論文 前6條
1 蘇培培;米存東;;中軸型脊柱關(guān)節(jié)炎骨侵蝕研究進(jìn)展[J];實(shí)用醫(yī)學(xué)雜志;2013年10期
2 劉俊;;心理干預(yù)對(duì)中軸型脊柱關(guān)節(jié)病患者心理影響分析[J];護(hù)士進(jìn)修雜志;2012年12期
3 戴巧定;唐婭琴;宋欣偉;;藥罐聯(lián)合塞來(lái)昔布治療中軸型脊柱關(guān)節(jié)病36例臨床觀察[J];江蘇中醫(yī)藥;2014年05期
4 牛林;張金山;梁成名;;補(bǔ)腎強(qiáng)督綜合療法對(duì)中軸型脊柱關(guān)節(jié)病患者的療效及生活質(zhì)量影響[J];安徽醫(yī)藥;2013年08期
5 朱燕兒;李國(guó)銘;譚麗珊;;MRI和CT在中軸型脊柱關(guān)節(jié)病早期診斷中的價(jià)值[J];新醫(yī)學(xué);2011年03期
6 ;[J];;年期
相關(guān)會(huì)議論文 前1條
1 米存東;梁彬彬;趙鋮;雷玲;;中軸型脊柱關(guān)節(jié)炎患者白細(xì)胞介素-23水平與骶髂關(guān)節(jié)磁共振改變的關(guān)系[A];第17次全國(guó)風(fēng)濕病學(xué)學(xué)術(shù)會(huì)議論文集[C];2012年
相關(guān)博士學(xué)位論文 前1條
1 張平;磁共振和能譜CT對(duì)中軸型脊柱關(guān)節(jié)炎骶髂關(guān)節(jié)炎的半定量分析[D];華中科技大學(xué);2015年
相關(guān)碩士學(xué)位論文 前8條
1 楊怡;中軸型與外周型脊柱關(guān)節(jié)炎合并骨質(zhì)疏松的臨床研究[D];吉林大學(xué);2016年
2 王玉;中藥熏洗治療中軸型脊柱關(guān)節(jié)病的臨床研究[D];大連醫(yī)科大學(xué);2016年
3 李坤鵬;北京首鋼公司中軸型脊柱關(guān)節(jié)炎患病率調(diào)查[D];中國(guó)人民解放軍軍醫(yī)進(jìn)修學(xué)院;2010年
4 羅貴;中軸型脊柱關(guān)節(jié)炎患者全脊柱磁共振成像的初步研究[D];中國(guó)人民解放軍醫(yī)學(xué)院;2014年
5 李偉;305例門診中軸型脊柱關(guān)節(jié)病臨床流行病學(xué)調(diào)查[D];廣西醫(yī)科大學(xué);2013年
6 崔銀風(fēng);骨化標(biāo)記物血清DKK-1與中軸型脊柱關(guān)節(jié)炎的相關(guān)性研究[D];山西醫(yī)科大學(xué);2014年
7 梁彬彬;中軸型脊柱關(guān)節(jié)炎患者血清IL-23水平與骶髂關(guān)節(jié)磁共振的意義[D];廣西醫(yī)科大學(xué);2012年
8 莊儒耀;中軸型脊柱關(guān)節(jié)病活動(dòng)性骶髂關(guān)節(jié)炎DWI、~1H-MRS成像意義初探[D];汕頭大學(xué);2011年
,本文編號(hào):2433155
本文鏈接:http://sikaile.net/yixuelunwen/nfm/2433155.html